Flindr Therapeutics, based in Oss in the Netherlands, is a private pre-clinical biotech company developing next-generation precision oncology treatments. The Company, previously called Immagene, was spun out of the Netherlands Cancer Institute (NKI) and Oncode Institute in 2020, by founders Prof Daniel Peeper, Prof Christian Blank and Dr Maarten Ligtenberg. Flindr is actively building a pipeline of highly promising, first-in-class precision oncology therapies identified through the ImmunoGram Drug Discovery Engine. It is backed by V-Bio Ventures, Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital, Oncode Oncology Bridge Fund, Swanbridge, Innovatiefonds Noord Holland, and BOM. Flindr has entered into a research collaboration with the NKI, and the VIB (Flanders Institute of Biotechnology).
Company Details
- Employees
- 2
- Founded
- -
- Address
- Oss, 5349ab, Nl
- co****@****ene.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- immagene.com
- Keywords
- for Renewable Energy.
- HQ
- Oss
Flindr (Formerly Immagene) Questions
Flindr (Formerly Immagene)'s website is immagene.com
Flindr (Formerly Immagene)'s LinkedIn profile is https://nl.linkedin.com/company/immagenebv
Flindr (Formerly Immagene) has
2 employees.
View email and phone details for 2
employees at Flindr (Formerly Immagene).
Flindr (Formerly Immagene)'s industry is
Biotechnology Research
Flindr (Formerly Immagene)'s top competitors are
Abnomx,
Astrivax Therapeutics,
Stant,
Camion,
Ruilwinkel Shop4nop,
Scenic Biotech,
Flindr Therapeutics,
Qtc Recruitment,
Immios B.v.,
Benno Therapeutics.
Flindr (Formerly Immagene)'s support email address is contact@immagene.com
Flindr (Formerly Immagene)'s categories are Biotechnology Research
Flindr (Formerly Immagene)'s founding year is 2020
